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Animal studies of effort-based choice behavior are being used to model effort-related 
motivational dysfunctions in humans. With these procedures, animals are offered a choice 
between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/
low reward options. Several previous studies have shown that dopamine (DA) uptake 
inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, 
can reverse the effort-related effects of the vesicular monoamine transport blocker 
tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport 
act as major stimulants that also release DA, and produce a number of undesirable 
side effects, there is a need to develop and characterize novel atypical DA transport 
inhibitors. (S)-CE-123 ((S)-5-((benzhydrylsulfinyl) methyl)thiazole) is a recently developed 
analog of modafinil with the biochemical characteristics of an atypical DA transport 
blocker. The present paper describes the enantioselective synthesis and initial chemical 
characterization of (S)-CE-123, as well as behavioral experiments involving effort-based 
choice and microdialysis studies of extracellular DA. Rats were assessed using the fixed 
ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behavior, 
decreasing lever pressing and increasing chow intake. (S)-CE-123 was coadministered 
at doses ranging from 6.0 to 24.0 mg/kg, and the highest dose partially but significantly 
reversed the effects of tetrabenazine, although this dose had no effect on fixed ratio 
responding when administered alone. Additional experiments showed that (S)-CE-123 
significantly increased lever pressing on a progressive ratio/chow feeding choice task and 
that the effective dose (24.0 mg/kg) increased extracellular DA in nucleus accumbens core. 
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INTRODUCTION
Motivational symptoms such as fatigue, anergia, and psychomotor 
slowing are seen in depression, Parkinson’s disease, and other 
disorders. These symptoms are often debilitating and can severely 
limit long-term functional outcomes (Demyttenaere et al., 2005; 
Salamone et al., 2006; Friedman et al., 2007; Fava et al., 2014; 
Rothschild et al., 2014; Chong et al., 2015; Salamone et al., 2016a; 
Salamone et al., 2016b; Salamone et al., 2016c; Salamone et al., 
2017). Moreover, motivational symptoms can be highly resistant 
to treatment with common antidepressants such as serotonin 
transporter (SERT) blockers (Cooper et al., 2014; Fava et al., 
2014; Rothschild et al., 2014). The catecholamine uptake inhibitor 
bupropion has shown some success in treating motivational 
symptoms in depressed people (Pae et al., 2007; Papakostas et al., 
2006; Cooper et al., 2014), and reports indicate that treatment 
with drugs that inhibit dopamine transporter (DAT), such as 
d-amphetamine and methylphenidate, can improve motivational 
function (Stotz et al., 1999). However, psychomotor stimulants 
that block DAT also can have undesirable effects, such as abuse 
liability and induction of psychotic symptoms. For these reasons, 
it is important to develop and assess drugs that are highly selective 
for DAT but show atypical neurochemical characteristics that 
may lower the side effect profile.
A recently synthesized and chromatographically separated 
analog of modafinil, (S)-CE-123 (Figure 1), is a highly selective 
atypical inhibitor of DAT that has been shown to enhance 
cognitive flexibility and reduce impulsivity in rats (Nikiforuk et al., 
2017). The present paper describes the enantioselective synthesis 
and initial characterization of (S)-CE-123. In addition, (S)-CE-123 
was assessed for its effects on effort-related aspects of motivation 
in rats. These behavioral pharmacology studies evaluated the 
motivational effects of (S)-CE-123 in rats using well-characterized 
tests of effort-based choice behavior, the concurrent fixed ratio 5 
(FR5)/chow feeding choice task, and the concurrent progressive 
ratio (PROG)/chow feeding choice task. Effort-related choice is 
studied using procedures that offer high-effort options leading 
to highly valued reinforcers vs. low-effort/low-reward options 
(Salamone and Correa, 2012; Salamone et al., 2016a; Salamone 
et al., 2016b; Salamone et al., 2016c; Hart et al., 2017; Salamone 
et al., 2017; Salamone et al., 2018). Considerable research has 
implicated dopamine (DA) transmission, particularly in nucleus 
accumbens core, in the regulation of effort-based choice; animals 
with impaired DA transmission (i.e., DA antagonism or depletion) 
show a shift from the high-effort option to the low-effort option, 
while enhancement of DA transmission reverses those effects 
(Sokolowski and Salamone, 1998; Salamone et al., 2002; Salamone 
et al., 2007; Floresco et al., 2008; Farrar et  al., 2010; Mai et al., 
2012; Hosking et al., 2015; Salamone et al., 2016a; Salamone et al., 
2016b; Salamone et al., 2016c). It has been suggested that animal 
models employing tests of effort-based decisión-making can 
be used to study functions that are related to aspects of human 
motivational dysfunction (Salamone et al., 2006; Salamone et al., 
2016a; Salamone et al., 2016b; Salamone et al., 2016c; Salamone 
et al., 2018). This strategy has been validated by clinical research 
showing that patients with major depression, Parkinson’s disease, 
and other disorders show a low-effort bias when tested on effort-
related choice procedures (Treadway et al., 2012; Yang et al., 2014; 
Chong et al., 2015; Barch et al., 2017).
Studies have shown that a low-effort bias can be induced in 
rats by several conditions associated with depressive symptoms, 
including stress (Shafiei et al., 2012; Bryce and Floresco, 2016), 
inflammatory challenge (Nunes et al., 2014; Yohn et al., 2016e), 
withdrawal from methamphetamine (Hart et al., 2018), and 
injections of the vesicular monoamine transporter type-2 inhibitor 
tetrabenazine (TBZ; Nunes et al., 2013; Randall et al., 2014; Yohn 
et al., 2015a; Yohn et al., 2015b). TBZ induces depressive symptoms 
in people (Frank, 2009; Frank, 2010; Guay, 2010) and has been 
used in classical animal models of depression (Tadano et al., 2000; 
Wang et al., 2010). By virtue of inhibiting vesicular monoamine 
transporter type-2, TBZ blocks DA storage, depletes brain DA, and 
reduces postsynaptic DA receptor signaling (Nunes et al., 2013). 
Across a variety of behavioral tests, TBZ shifts choice behavior and 
In summary, (S)-CE-123 has the behavioral and neurochemical profile of a compound 
that can block DA transport, reverse the effort-related effects of tetrabenazine, and 
increase selection of high-effort progressive ratio responding. This suggests that (S)-CE-
123 or a similar compound could be useful as a treatment for effort-related motivational 
dysfunction in humans.
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FIGURE 1 | Structure of the novel atypical dopamine reuptake inhibitor  
(S)-CE-123 ((S)-5-((benzhydrylsylfinyl)methyl)thiazole).
Effort-Related Effects of (S)-CE-123Rotolo et al.
3 June 2019 | Volume 10 | Article 682Frontiers in Pharmacology | www.frontiersin.org
induces a low-effort bias, and the reallocation of behavior from 
high- to low-effort options that is produced by TBZ is not due to 
alterations in food preference or hedonic taste reactivity, reduced 
apetite, or impairments in reference memory (Randall et al., 2012; 
Nunes et al., 2013; Randall et al., 2014; Pardo et al., 2015; Yohn 
et al., 2015a). On operant behavior tests that give animals the choice 
between lever pressing on a FR5 or PROG schedule for a preferred 
food vs. approaching and consuming a less preferred lab chow 
(Nunes et al., 2013; Randall et al., 2014; Yohn et al., 2016a; Yohn 
et al., 2016b; Yohn et al., 2016c), TBZ reliably decreases working 
for food by lever pressing but actually increases consumption of 
the concurrently available chow. TBZ in this dose range does not 
reduce consumption of either type of food that is used in these 
studies nor does it affect preference as measured in free-feeding 
preference tests (Nunes et al., 2013). Also, the effects of TBZ on 
operant choice procedures differ substantially from the effects 
of reinforcer devaluation, as well as appetite suppressant drugs 
(Randall et al., 2012; Randall et al., 2014). These effects of TBZ are 
not reversed by the SERT blockers fluoxetine and citalopram, or 
by the norepinephrine transporter (NET) inhbitor desipramine 
(Yohn et al., 2016a; Yohn et al., 2016b), but they are attenuated by 
several drugs that block DAT, including bupropion, GBR12909, 
lisdexamfetamine, methylphenidate, and modafinil (Nunes et al., 
2013; Randall et al., 2014; Salamone et al., 2016a; Salamone et al., 
2016b; Yohn et al., 2016a; Yohn et al., 2016b; Yohn et al., 2016c). 
Drugs that inhibit DAT, such as bupropion, lisdexamfetamine, and 
PRX-14040, also have been shown to increase the motivation to 
work for food reinforcers in more highly demanding behavioral 
tasks, such as the PROG/chow feeding choice task (Randall 
et al.,  2015; Yohn et al., 2016b; Yohn et al., 2016c; Yohn et al., 
2016d). In view of these results, the present studies investigated 
the ability of (S)-CE-123 to attenuate the effort-related effects of 
TBZ in rats tested on the concurrent FR5/chow feeding choice 
task and to enhance exertion of effort in rats assessed with the 
PROG/chow feeding choice task. An additional experiment 
studied the effects of the behaviorally effective dose of (S)-CE-
123 (24.0 mg/kg) on extracelular DA in nucleus accumbens using 
microdialysis methods.
MATERIALS AND METHODS
Synthesis of (S)-CE-123
Synthesis of 5-(Chloromethyl)Thiazole Hydrochloride
A (0.63 g, 5.5 mmol) was dissolved in 20 ml of dichloromethane 
(DCM) and dunked in an ice bath. B (0.40 ml, 5.5 mmol) was 
gradually dripped in, and the reaction was allowed to proceed 
overnight. The reaction mixture was concentrated in vacuo, 
and the obtained substance was dried in high vacuum to 
remove thionyl chloride and water excess (the product is highly 
hygroscopic) to afford 0.93  g of product C as yellow powder 
(yield >95%, quantitative).
Synthesis of [(Diphenylmethyl)Sulfanyl]
Methanimideamide Hydrobromide
A (1.29 g, 7 mmol) was dissolved in 30 ml of methanol (MeOH) in 
a 100-ml three-necked round-bottomed flask, B (0.61 g, 8 mmol) 
was added, and the reaction mixture was refluxed (external 
temperature 87–90°C) for 30 min. C (3.64 ml, 32.2 mmol) was 
added in a dropwise manner over the course of half an hour, and 
the reaction mixture was further refluxed for an additional 3 h.
The reaction mixture was cooled down to room temperature, 
MeOH was evaporated, and the remaining substance was 
suspended in 30 ml of DCM, stirred for half an hour, and 
filtered through a Büchner funnel to remove unreacted A. The 
solid residue was washed with additional 30 ml of DCM and 
subsequently suspended in 30  ml of water, stirred for half an 
hour, and filtered through a Büchner funnel to remove unreacted 
B. The residue was washed with 30 ml of water and dried to give 
1.62 g of product D as fine, white powder (yield 71%).
Synthesis of 5-((Benzhydrylthio)Methyl)Thiazole
A (1.62 g, 5 mmol) was dissolved in 30 ml of MeOH, and B (0.93 g, 
5.5 mmol) was added and dissolved, upon which C (3.45 g, 25 mmol) 
was introduced, and the reaction mixture was refluxed for 4 h 
(external temperature was 87–90°C).
The hot reaction mixture was filtered through a Büchner 
funnel to remove the majority of K2CO3, and methanol was 
evaporated under reduced pressure. The remaining substance 
was suspended in 50  ml of water, and reaction products were 
extracted with ethyl acetate (3 × 75 ml). The extracts were pooled, 
dried over anhydrous Na2SO4, filtered and condensed under 
reduced pressure to afford an oily mixture that was purified by 
column chromatography on silica gel (2.5% solution of MeOH 
in DCM was used as eluent), and recrystallized from petroleum 
ether to yield 1.25 g of the desired product D as white crystals 
(yield 84%).
Synthesis of (S)-5-((Benzhydrylsulfinyl)Methyl)
Thiazole ((S)-CE-123)
A (1.25g, 4.25 mmol) was dissolved in 25 ml of acetone in a 
100-ml round-bottomed flask. B (0.37 ml, 1.25 mmol), C (0.43 ml, 
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2.5 mmol), and D (11.25 µL, 0.625 mmol) were added to the 
mixture, which was stirred for 5 min to achieve homogeneity at 
the room temperature and then refluxed for 1 h at 65°C (external 
temperature). The mixture was given 15 min to cool down to 
room temperature, E (0.15 ml, 0.85 mmol) was added, and after 
10 min of stirring, F (0.78 ml, 4.25 mmol) was added, and the 
reaction was allowed to proceed for 20 h.
Acetone was evaporated from the mixture, and the oily 
orange–brown residue was purified by column chromatography 
on silica gel (2.5% solution of methanol in DCM was used as the 
mobile phase) to give 0.99 g of the final product G, as white solid 
(yield 74%).
In Vivo Behavioral Pharmacology
Animals
For the behavioral pharmacology experiments, adult male 
Sprague-Dawley rats (Envigo Sprague-Dawley, Indianapolis, 
IN, USA; weights 275–299 g upon arrival) were pair-housed in 
a colony maintained at 23°C, with a 12-h light/dark cycle (lights 
on 07:00). Rats were food deprived to 85% of their free-feeding 
body weight for operant training and allowed modest growth 
throughout the experiment. Water was available ad libitum in the 
home cages. Animal protocols were approved by the University of 
Connecticut Institutional Animal Care and Use Committee, and 
the studies were conducted according to National Institutes of 
Health guidelines. For the in vivo microdialysis experiment, adult 
male Sprague-Dawley rats (Harlan Italy; weights 275–300 g upon 
arrival) were used. Rats were housed four per cage, in standard 
plastic cages with wood chip bedding, maintained at 22 ± 2°C 
and 60% humidity with a 12-h light/dark cycle (lights on 07:00). 
Water and standard laboratory rodent chow (Mucedola, Settimo 
Milanese, Italy) were provided ad libitum in the home cage. All 
animal experiments were carried out in accordance with the 
Guidelines for the Care and Use of Mammals in Neuroscience 
and Behavioral Research according to Italian (D.L. 116/92 and 
152/06) and European Council (609/86 and 63/2010) directives 
and in compliance with the approved animal policies by the 
Ethical Committee for Animal Experiments (CESA, University 
of Cagliari) and the Italian Ministry of Health (Aut. N. 162/2016- 
PR). All efforts were taken to minimize pain and suffering and to 
reduce the number of animals used.
Behavioral Procedures
FR5/Chow Feeding Choice Task
Behavioral sessions were conducted in operant chambers (28 × 
23 × 23 cm3; Med Associates, Fairfax, VT) with 30-min sessions 
5  days/week. Rats were initially trained to lever press on a 
continuous reinforcement FR1 schedule (high-carbohydrate 
45-mg pellets, Bio-Serv, Frenchtown, NJ) and then shifted 
to the FR5 schedule. After 5 weeks of training on the FR5 
schedule, chow was introduced. Weighed amounts of laboratory 
chow (Laboratory Diet, 5P00 Prolab RMH 3000, Purina Mills, 
St. Louis, MO; typically 15–20 g) were concurrently available on 
the floor of the chamber during the FR5/chow feeding choice 
task sessions. At the start of each session, it was confirmed that 
the pieces of weighed chow were larger than the spaces between 
the bars that make up the floor of the chamber, so they could 
not fall through. At the end of each 30-min session, rats were 
immediately removed from the chambers, number of lever 
presses was recorded, and the amount of chow consumed was 
determined by weighing the remaining food (including spillage 
from a tray beneath the floor of the chamber). Rats were trained 
on the FR5/chow feeding choice procedure for 5 weeks, after 
which drug testing began. On baseline and drug treatment days, 
rats consumed all of the operant pellets that were delivered 
during each session.
PROG/Chow Feeding Choice Task
Behavioral sessions were conducted in operant chambers with 
30-min sessions 5 days/week. Rats were initially trained to 
lever press on a continuous reinforcement FR1 schedule (high-
carbohydrate 45-mg pellets, Bio-Serv) and then shifted to 
the PROG schedule (Randall et al., 2012; Randall et al., 2014; 
Randall et al., 2015). For PROG sessions, the ratio started at 
FR1 and was increased by one additional response every time 
15 reinforcements were obtained (FR1 × 15, FR2 × 15, etc.). A 
“time-out” feature deactivated the response lever for the rest of 
the session whenever 2 min elapsed without a completed ratio. 
After 9 weeks of training on the PROG schedule, chow was 
introduced. Weighed amounts of laboratory chow (Laboratory 
Diet, 5P00 Prolab RMH 3000, Purina Mills; typically 15–20 g) 
were concurrently available on the floor of the chamber during 
the PROG/chow feeding choice task sessions. At the end of 
each 30-min session, rats were immediately removed from 
the chambers, number of lever presses was recorded, and the 
amount of chow consumed was determined by weighing the 
remaining food (including spillage from a tray beneath the floor 
of the chamber). Rats were trained on the PROG/chow feeding 
choice procedure for 5 weeks, after which drug testing began. 
On baseline and drug treatment days, rats consumed all of the 
operant pellets that were delivered during each session.
Drug Treatments and Dose Selection
(S)-CE-123 ((S)-5-((benzhydrylsulfinyl)methyl)thiazole) was 
obtained from the Lubec Laboratory (University of Vienna, Austria) 
and dissolved in dimethyl sulfoxide (DMSO) (10%), Tween 80 
(15%), and 0.9% saline (75%). The DMSO/Tween 80/saline solution 
was administered as the vehicle control. TBZ (9,10-dimethoxy-
3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-
2-one) was obtained from Tocris Bioscience (Ellisville, MO) and 
was dissolved in DMSO (20%) and 0.9% saline (80%) and was 
titrated with microliter quantities of 1.0 N HCl until the solid drug 
was in solution at a pH of 4.0–4.5. The DMSO/saline solution was 
administered as the vehicle control. The dose of 1.0 mg/kg TBZ was 
based on extensive piloting in our laboratory. The doses of (S)-CE-
123 were selected based on extensive pilot studies and information 
about its relative affinity for DAT.
Behavioral Pharmacology Experiments
Trained rats (n = 8) were administered either TBZ (1.0 mg/kg) or 
vehicle, and (S)-CE-123 (6.0, 12.0, and 24.0 mg/kg) or vehicle, via 
intraperitoneal (IP) injections on drug testing days. Rats received 
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TBZ or vehicle 120 min before testing and (S)-CE-123 or vehicle 
30 min before testing. The experiment used a within-groups 
design, with each rat receiving each drug treatment in a randomly 
varied order (one treatment per week, with none of the treatment 
sequences repeated across different animals). Sample size was 
determined based on information obtained from pilot studies 
done in our laboratory. Experimenter blinding was not necessary 
due to the objective nature of the data collection. The following 
five treatment combinations were given: TBZ vehicle + (S)-CE-123 
vehicle; 1.0 mg/kg TBZ + (S)-CE-123 vehicle; 1/0 mg/kg TBZ + 
6.0 mg/kg (S)-CE-123; 1.0 mg/kg TBZ + 12.0 mg/kg (S)-CE-123; 
1.0 mg/kg TBZ + 24.0 mg/kg (S)-CE-123. The endpoint of the 
experiment was marked by the completion of the last scheduled 
drug treatments for each rat, after having received each drug 
treatment in a randomly varied order.
Following the initial behavioral experiment, (S)-CE-123 was 
tested on a different group of rats (n = 7) to assess whether it had 
a behavioral effect when administered alone. Rats were trained on 
the FR5/chow feeding choice task as described previously. Thirty 
minutes prior to the testing session, rats were administered either 
vehicle or 24.0 mg/kg (S)-CE-123. One week later, rats received 
either vehicle or 24.0 mg/kg (S)-CE-123 so that the treatment 
orders were counterbalanced. Only the highest dose of (S)-CE-
123 (24.0 mg/kg) was chosen for testing in this paradigm.
A third behavioral experiment was conducted to determine if 
(S)-CE-123 had an effect on rats’ behavior on the PROG/chow 
feeding choice task when administered alone. Thirty minutes 
prior to the testing session, trained rats (n = 15) were administered 
either vehicle or 6.0, 12.0, or 24.0 mg/kg (S)-CE-123. This 
experiment used a within-groups design, with each rat receiving 
each drug treatment in a randomly varied order. Treatments were 
administered once per week over the course of 4 weeks.
In Vivo Microdialysis
Surgery
Male Sprague-Dawley rats (275–300 g; Harlan, Italy) were 
anesthetized with fentanyl (0.06 mg/kg IP), placed in a stereotaxic 
apparatus, and implanted with vertical dialysis probes prepared 
as previously described (De Luca et al., 2016) with 1.5  mm 
dialyzing portion. According to the rat brain atlas of Paxinos and 
Watson (1998), unilateral probes were implanted in the nucleus 
accumbens shell (A +2.2, L +1.0 from bregma, V −7.8 from dura; 
n = 10) or nucleus accumbens core (A +1.4; L +1.6 from bregma, 
V −7.6 from dura; n = 7).
Analytical Procedure
On the day following surgery, animals were connected to an 
infusion pump, and probes were perfused with Ringer’s solution 
(147 mM NaCl, 4 mM KCl, 2.2 mM CaCl2) at a constant rate of 
1 µl/min. After rinsing for at least 1 h, dialysate samples (20 µl) 
were collected every 20 min and injected into an HPLC equipped 
with a reverse phase column (C8 3.5 µm, Waters, USA) and a 
coulometric detector (ESA, Coulochem II) to quantify DA. The 
electrodes of the analytical cell were set at +125 mV (oxidation) 
and −175 mV (reduction) to detect dopamine. The mobile phase 
composition was: 50 mM NaH2PO4, 0.1 mM Na2EDTA, 0.5 mM 
n-octylsulfate, and 15% (v/v) methanol. The sensitivity of the 
assay for DA was 5 fmol/sample. When the DA did not differ 
more than 10% in three consecutive samples, the average value 
was considered as the basal level of DA. The animals were treated 
with vehicle or (S)-CE-123 24.0 mg/kg IP, and monoamine levels 
were monitored for 3 h from the start of the treatment.
Histology
At the end of the experiment, animals were sacrificed, and brains 
were removed and stored in formalin (8%). Brains were sliced 
and stained with Nissl stain for histological examination in order 
to verify the correct placement of the microdialysis probes.
Statistical Analysis
Behavioral Pharmacology Experiments
Total number of lever presses and gram quantity of chow intake 
from the 30-min sessions were analyzed using repeated measures 
ANOVA. A statistical program (SPSS, version 25) was used to 
perform all analyses. Since there were significant overall F values 
for the three behavioral measures being used, nonorthogonal 
planned comparisons were performed, using the overall error 
term to assess differences between each treatment and the 
control condition. The number of comparisons was restricted to 
the number of treatments minus one (Keppel, 1991). Statistical 
outliers were predefined as any point that is more than two 
standard deviations from the mean. No data from this study were 
excluded as outliers. Microdialysis data were expressed as percent 
of the last three baseline samples and were analyzed by a 4 group × 
12 sample factorial ANOVA with repeated measures on the sample 
factor. Since there was a significant group × sample interaction, 
so subsequent analysis of simple main effects examined the effect 
of the sample factor for each of the four groups. Results from 
treatments showing significant overall changes were subjected to 
Tukey’s tests for post hoc comparisons, with significance at p < 0.05.
RESULTS
FR5/Chow Feeding Choice Task
Figure 2 shows the results of the FR5/chow feeding choice 
experiment. TBZ shifted effort-based choice, decreasing lever 
pressing and increasing chow intake. Repeated measures ANOVA 
revealed that there was an overall significant effect of drug treatment 
on lever pressing [F(4,28) = 34.625, p < 0.001] (Figure 2A). 
Planned comparisons showed that TBZ significantly decreased 
lever pressing compared with vehicle treatment {TBZ/Veh vs. 
Veh/Veh [F(1,28) = 105.87, p < 0.001]}. There was also significant 
overall effects of drug treatment on chow intake [F(4,28) = 27.280, 
p < 0.001], and TBZ alone significantly increased chow intake 
relative to vehicle treatment {TBZ/Veh vs. Veh/Veh [F(1,28) = 
66.625, p < 0.001]} (Figure 2B). Additional planned comparisons 
revealed that coadministration of the dose of 24.0 mg/kg (S)-CE-
123 with TBZ significantly attenuated the effects of TBZ on lever 
pressing {TBZ plus 24.0 mg/kg vs. TBZ/Veh [F(1,28) = 13.2866, 
p < 0.01]} and chow intake {TBZ plus 24.0 mg/kg vs. TBZ/Veh 
[F(1,28) = 61.014, p < 0.001]}.
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As shown in Figure 3, there was no effect of drug treatment 
relative to vehicle on lever pressing or chow intake on the FR5/
chow feeding choice task when 24.0 mg/kg (S)-CE-123 was 
administered alone prior to testing. Repeated measures ANOVA 
indicated no significant difference between rats treated with 
24.0 mg/kg (S)-CE-123 and vehicle-treated rats on lever pressing 
[F(1,6) = 0.012, p = n.s]. (Figure 3A) or chow intake [F(1,6) = 
0.030, p = n.s]. (Figure 3B).
PROG/Chow Feeding Choice Task
(S)-CE-123 was tested for its behavioral effect on the PROG/chow 
feeding choice task when administered alone (i.e., in the absence 
of TBZ). Repeated measures ANOVA revealed an overall main 
effect of drug treatment on lever pressing [F(3,42) = 3.165, p < 
0.05], and planned comparisons demonstrated that lever presses 
were significantly increased at 24.0 mg/kg (S)-CE-123 compared 
with vehicle treatment (Veh vs. 24.0 mg/kg (S)-CE-123 [F(1,42) = 
4.061, p < 0.05] (Figure 4A). Drug treatment with (S)-CE-123 also 
had a significant effect on chow intake during the PROG/chow 
FIGURE 2 | The effects of the DAT blocker (S)-CE-123 on TBZ-induced 
changes in performance on the concurrent lever pressing/chow-feeding 
choice procedure. Rats (n = 8) received intraperitoneal injections of vehicle 
plus vehicle (v/v), 1.0 mg/kg TBZ plus vehicle (TBZ/V), or TBZ plus 6.0, 
12.0, or 24.0 mg/kg doses of (S)-CE-123. (A) Mean (± SEM) number of 
lever presses (FR5/chow schedule) during the 30-min session. #p < 0.001, 
TBZ plus vehicle significantly differed from vehicle plus vehicle; *p < 0.01, 
TBZ plus 24.0 mg/kg (S)-CE-123 significantly differed from TBZ plus vehicle. 
(B) Mean (± SEM) gram quantity of chow intake. #p < 0.001, TBZ plus 
vehicle significantly differed from vehicle plus vehicle; **p < 0.001, TBZ 
plus 24.0 mg/kg (S)-CE-123 significantly differed from TBZ plus vehicle.
FIGURE 3 | The effects of the DAT blocker (S)-CE-123 on performance on 
the concurrent lever pressing/chow-feeding choice procedure. Rats (n = 7) 
received intraperitoneal injections of vehicle (Veh), or 24.0 mg/kg (S)-CE-123. 
(A) Mean (± SEM) number of lever presses (FR5/chow schedule) during the 
30-min session. Lever presses of rats treated with 24 mg/kg (S)-CE-123 
did not significantly differ from rats treated with vehicle (p = n.s.). (B) Mean 
(± SEM) gram quantity of chow intake. Chow intake of treated with 24 mg/kg 
(S)-CE-123 did not significantly differ from rats treated with vehicle (p = n.s.).
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session, indicated by a repeated measures ANOVA [F(3,42)  = 
13.771, p < 0.001], with a significant reduction in chow intake 
at the 24.0 mg/kg dose compared with vehicle (Veh vs. 24.0 mg/kg 
(S)-CE-123 [F(1,42) = 28.107, p < 0.001] (Figure 4B).
Microdialysis
One-way ANOVA revealed no differences in basal DA levels 
between nucleus accumbens shell vehicle (mean 130.46 fmoles 
DA/20 µl; SEM 19.01) and nucleus accumbens shell 24.0 mg/kg 
(S)-CE-123 (mean 90.65 fmoles DA/20 µl; SEM 12.17) conditions 
[F(1,9) = 2.411, p = n.s.], or nucleus accumbens core vehicle 
(mean 91.28 fmoles DA/20 µl; SEM 27.37) and nucleus accumbens 
core 24.0 mg/kg (S)-CE-123 (mean 90.25 fmoles DA/20 µl; SEM 
17.12) conditions [F(1,6) = 0.001, p = n.s.]. A 4 group × 12 sample 
repeated measures factorial ANOVA revealed a significant overall 
effect of treatment group [F(3,13) = 29.680, p < 0.001], a significant 
effect of sample [F(11,143) = 6.756, p < 0.001], and a significant 
treatment × sample interaction [F(33,143) = 8.019, p < 0.001] 
(Figure 5). Analysis of simple effects in which each condition was 
analyzed separately showed that there was a significant increase in 
extracellular DA in the nucleus accumbens core in the group that 
received 24.0 mg/kg (S)-CE-123 [F(11,33) = 11.950, p < 0.001]. 
Tukey’s tests indicated that 24.0 mg/kg (S)-CE-123 administration 
increased nucleus accumbens core DA significantly from baseline 
at samples taken 40–180 min after injection (p < 0.05). Analysis of 
simple effects also showed that there was a significant difference 
in extracellular DA in the nucleus accumbens shell in the group 
treated with 24.0 mg/kg (S)-CE-123 [F(11,33) = 7.049, p < 0.001] 
from baseline, and a Tukey’s test indicated a significant reduction 
at 100  min after injection (p < 0.05). Injections of vehicle had 
no significant effect on extracellular DA levels in either nucleus 
accumbens core or shell (Figure 5). Figure 6 depicts the placements 
of dialysis probes in the nucleus accumbens core and shell.
DISCUSSION
The synthesis of (S)-CE-123 afforded highly pure desired 
enantiomer, and NMRs and mass spectroscopy methods 
yielded spectra unambiguously identifying the compound (see 
Supplementary Materials). In previous studies, the absolute 
configuration was characterized as the (S)-enantiomer that was 
shown to be stronger at inhibiting DAT than the (R)-enantiomer 
FIGURE 4 | The effects of the DAT blocker (S)-CE-123 on performance on 
the concurrent lever pressing/chow-feeding choice procedure. Rats (n = 15) 
received intraperitoneal injections of vehicle (Veh), 6.0, 12.0, or 24.0 mg/kg 
doses of (S)-CE-123. (A) Mean (± SEM) number of lever presses (PROG/
chow schedule) during the 30-min session. *p < 0.05, 24.0 mg/kg (S)-CE-
123 significantly differed from vehicle. (B) Mean (± SEM) gram quantity 
of chow intake. **p < 0.001, 24.0 mg/kg (S)-CE-123 significantly differed 
from vehicle.
FIGURE 5 | Effect of vehicle or 24.0 mg/kg (S)-CE-123 on extracellular DA 
in the nucleus accumbens core and shell measured by microdialysis. Mean 
(± SEM) extracellular DA (expressed as percent baseline) in 20-min samples 
across 180 min. Three baseline samples were collected prior to injection, 
followed by nine postinjection samples. *Significantly different from vehicle, 
p < 0.05.
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(Nikiforuk et al., 2017; Kristofova et al., 2018). In uptake 
inhibition assays conducted in HEK293 cells stably expressing 
human isoforms of DAT, NET, and SERT, the EC50 for inhibition 
of DAT by (S)-CE-123 was reported to be 2.76 × 10-6 M, which 
was 30-fold selective relative to inhibition of NET and more than 
400-fold selective compared with SERT inhibition (Nikiforuk 
et  al., 2017, Supplementary Figure 17A). Moreover, (S)-CE-
123 is able to penetrate the blood–brain barrier after systemic 
injection (Kristofova et al., 2018). In the present paper, we report 
the first enantioselective synthesis of (S)-CE-123, as well as 
behavioral studies focusing on effort-related choice behavior.
The behavioral studies sought to provide an initial 
characterization of the behavioral effects of the novel atypical 
DAT inhibitor, (S)-CE-123, in terms of its ability to alter effort-
related choice behavior in rats. Specifically, one of the experiments 
employed a task designed to measure effort-related choice, which 
was used to assess the ability of (S)-CE-123 to reverse the effort-
related effects of TBZ. In this experiment, rats trained on the 
FR5/chow feeding choice task shifted from the high-effort option 
(FR5 lever pressing) to the low-effort option (chow intake) when 
treated with TBZ, consistent with previous findings (Nunes 
et al., 2013; Randall et al., 2014; Yohn et al., 2015a; Yohn et al., 
2016b; Yohn et al., 2016c). Several previous studies with TBZ 
have shown that these shifts in effort-based choice are not due 
to changes in food intake, food preference, sucrose preference, 
motor incapacity, or reference memory and do not resemble 
the effects of appetite suppressant drugs or reward devaluation 
by pre-feeding (Nunes et al., 2013; Randall et al., 2014; Pardo 
et al., 2015; Yohn et al., 2015a). Coadministration of 24.0 mg/kg 
(S)-CE-123 with TBZ produced a significant but partial reversal 
of the effects of TBZ, as indicated by an increased selection of 
FR5 lever pressing (Figure 2A) and a decrease in chow intake 
(Figure  2B) compared with TBZ plus vehicle. In a parallel 
control experiment in rats tested on the same task, 24.0 mg/kg 
(S)-CE-123 administered in the absence of TBZ did not have any 
effect on lever pressing (Figure 3A) or chow intake (Figure 3B).
In order to develop a more comprehensive characterization of 
the effort-related actions of monoamine uptake inhibitors, it also 
is important to administer them alone, in the absence of a drug 
like TBZ, because that would allow for the assessment of both 
increases and decreases in performance, in the absence of a drug 
condition like TBZ, which induces an impairment. In previous 
studies, the PROG/chow feeding choice task has been used to 
assess the ability of drugs to enhance selection of high-effort 
PROG lever pressing (e.g., Randall et al., 2012; Randall et al., 
2015). This task is especially well suited for such an assessment 
because unlike the FR5/chow feeding choice task, baseline lever 
pressing rates are relatively low on the PROG component due 
to the increasing response requirement of the PROG schedule. 
Thus, as the ratio work requirement gets gradually higher, 
animals eventually shift over to chow consumption (Randall 
et al., 2012; Randall et al., 2014; Randall et al., 2015). Previous 
research has demonstrated that the NET inhibitors desipramine 
and atomoxetine, as well as the SERT inhibitor fluoxetine, all fail 
to increase PROG lever pressing in rats tested on the PROG/
chow feeding choice procedure (Yohn et al., 2016d). In contrast, 
drugs that inhibit DAT, including bupropion, lisdexamfetamine, 
PRX-14040, MRZ-9547, and GBR 12909, all have been shown 
to increase selection of PROG responding on this task (Sommer 
et al., 2014; Randall et al., 2015; Yohn et al., 2016b; Yohn et al., 
2016c; Yohn et al., 2016d). In the present studies, (S)-CE-123 
was shown to significantly increase PROG lever pressing and 
decrease chow intake in rats tested on the PROG/choice procedure 
(Figure 4). Furthermore, the effective dose of (S)-CE-123 in both 
the TBZ reversal and PROG/chow feeding choice studies, 24.0 mg/
kg, significantly increased extracellular DA in nucleus accumbens 
core as measured by microdialysis (Figure 5). In previous studies 
in which PROG lever pressing and bupropion-induced changes in 
extracellular DA were investigated in separate groups of animals 
(Randall et al., 2015), the magnitude of the increases in PROG 
lever pressing and accumbens core DA shown after administration 
of 20.0 mg/kg bupropion were comparable with those shown in the 
present studies with 24.0 mg/kg (S)-CE-123.
It is not clear why extracellular DA did not increase in the 
nucleus accumbens shell after injections of (S)-CE-123. In a 
recent study, Camats-Perna et al. (2019) reported that (S)-CE-123 
at doses of 10.0 and 100.0 mg/kg increased extracellular DA in the 
nucleus accumbens of mice. However, given the small size of the 
mouse brain, and the active surface area of the probe, it is evident 
that both core and shell DA contributed to this finding. Previous 
studies have looked at the neurochemical effects of modafinil, 
the parent compound for (S)-CE-123. Bobak et al. (2016) used 
voltammetry methods to study the effects of modafinil on 
extracellular DA in rats; they employed a ventral striatal electrode 
placement that did not specifically target the shell and observed 
that doses of modafinil up to 100.0 and 300.0  mg/kg increased 
DA transmission. Mereu et al. (2017) conducted a microdialysis 
study  of core and shell DA in mice and observed that while 
17.0  mg/kg modafnil did not significantly increase shell DA, 
30.0 mg/kg produced a modest increase in DA in core and shell, 
FIGURE 6 | Histology figure showing microdialysis probe placements for 
nucleus accumbens core (co) and shell (sh). Drawings are from Paxinos and 
Watson (1998). CPu, caudate putamen.
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while higher doses (100.0 and 300.0 mg/kg) produced very robust 
increases. These high doses of modafinil (100.0 and 300.0 mg/kg) 
are 10 times the behaviorally effective doses of modafinil that we 
have used in our rat studies with effort-based choice (e.g. 7.5, 15.0, 
and 30.0 mg/kg; Salamone et al., 2016a).
Despite the negative findings with shell DA, core DA did 
substantially increase in the present study, and previous work has 
shown that the core subregion is a critical site at which effort-based 
choice is regulated. Sokoloski and Salamone (1998) reported 
that the shift from lever pressing to chow intake in rats tested 
on the concurrent FR5/chow feeding choice task was produced 
after injections of the neurotoxic agent 6-hydroxydopamine 
into nucleus accumbens core but not the shell. Ghods-Sharifi 
and Floresco (2010) showed that a low-effort bias in rats tested 
on an effort-discounting task was produced after inactivation 
of the nucleus accumbens core but not the shell. Randall et al. 
(2012) observed that a postsynaptic marker of DA transmission 
(expression of DA and cyclic AMP dependent phosphoprotein 
phosphorylated at the threonine-34 site) was significantly higher 
in animals with high PROG lever pressing compared with low 
PROG lever pressing; this was seen in accumbens core but not 
shell. Furthermore, local accumbens core injections of the DA 
antagonist flupenthixol (Farrar et al., 2010) and TBZ (Nunes 
et al., 2013) shifted choice behavior from FR5 lever pressing to 
chow intake, while injections into overlying neostriatum did not.
Several lines of evidence indicate that DAT blockers can have 
pro-motivational effects in animal models (Nunes et al., 2013; 
Randall et al., 2015; Sommer et al., 2014; Yohn et al., 2016a; Yohn 
et al., 2016b; Yohn et al., 2016c; Yohn et al., 2016d). Although 
DAT inhibition is a commonly used descriptor for a broad class 
of drugs, there is considerable heterogeneity within this group of 
compounds. For example, amphetamines such as d-amphetamine 
and methamphetamine are not only competitive inhibitors of 
DAT but also substrates that are transported into the neuronal 
terminal and stimulate release (Ferris et al., 2011). Cocaine is a 
classical DAT inhibitor with a rapid onset and offset of action 
(Tanda et al., 2013). Unfortunately, most classical DAT inhibitors 
and releasing agents have a well-characterized abuse liability 
(Todtenkopf and Carlezon, 2006; Ostlund et al., 2014; Dong 
et al., 2017), which limits their therapeutic utility for treating 
motivational dysfunction in psychiatry. However, not all drugs 
that bind to the DAT share cocaine’s behavioral profile or have 
a high potential for abuse. Over the last several years, atypical 
DAT inhibitors have been under development, which have 
characteristics that differ from cocaine. GBR12909 was developed 
as a potential treatment for cocaine addiction (Rothman et al., 
2008). GBR12909 blocks many of the effects of cocaine and on its 
own has produced mixed effects in terms of cocaine-like actions; 
it did not produce psychostimulant effects in people in the dose 
ranges tested (Sogaard et al., 1990; Preti, 2000), and although 
it supported self-administration in primates, its efficacy was 
lower than that of cocaine (Woolverton et al., 2001). Although 
GBR12909 was discontinued as a potential treatment for cocaine 
abuse due to its cardiac effects, analogs of GBR12909 have been 
studied for their atypical binding characteristics (Rothman 
et al., 2008). The DAT has multiple functional conformations, and 
several benztropine analogs have been shown to bind to the DAT 
in a manner that is distinct from that of cocaine (Schmitt et al., 
2008; Kohut et al., 2014). Some of these benztropine analogs have 
been shown to increase extracellular DA in nucleus accumbens, 
albiet over a much longer time course than cocaine (Tanda et al., 
2013). Unlike cocaine, these drugs failed to induce conditioned 
place preference (Tanda et al., 2013).
(S)-CE-123 is an analog of modafinil, which also binds to the 
DAT with an atypical profile (Schmitt and Reith, 2011; Cao et al., 
2016). Modafinil inhibits DAT and increases extracellular DA over 
a broad time course (Mereu et al., 2017), and while this drug has 
been shown to have cognitive enhancing and pro-motivational 
effects, it has a relatively low abuse liability (Mereu et al., 2013; 
Müller et al., 2013). Modafinil has been reported to improve 
fatigue symptoms in depressed patients (Lam et al., 2007), and 
recent studies from our laboratory have shown that modafinil 
can reverse the low-effort bias induced by TBZ in rats (Salamone 
et al., 2016a; Yohn et al., 2016c). When bound to the DAT, (S)-CE-
123 also has an atypical pattern compared with cocaine, in that 
it interacts with the negatively charged ASP79 locus (Kristofova 
et al., 2018). Moreover, (S)-CE-123 acts as a highly selective 
atypical inhibitor of DAT relative to NET and SERT and is more 
selective for DAT than modafinil (Kristofova et al., 2018). (S)-
CE-123 has been shown to enhance cognitive flexibility, improve 
memory acquisition and retrieval, and reduce impulsivity in rats 
(Nikiforuk et al., 2017; Kristofova et al., 2018), and in the present 
studies, it reverses the motivational impairments induced by TBZ 
and increases selection of high-effort PROG lever pressing.
In the present studies, a partial reversal of the effort-related 
motivational dysfunction induced by TBZ was achieved with 
(S)-CE-123 administration in a dose range of 6.0–24.0 mg/kg. 
The efficacy of (S)-CE-123 at restoring lever pressing appears to 
be lower than that of bupropion, GBR12909, lisdexamfetamine, 
methylphenidate, and modafinil in rats tested on similar 
procedures (Nunes et al., 2013; Salamone et al., 2016a; Yohn 
et  al., 2016a; Yohn et al., 2016b; Yohn et al., 2016c), although 
most drugs that block DAT tend to produce only partial reversals 
of the effects of TBZ (i.e., approximately 60–85% restoration of 
responding). Nevertheless, (S)-CE-123 was highly efficacious at 
reversing the TBZ-induced increase in chow intake (Figure 2B), 
which may indicate that this drug also has appetite-suppressant 
actions. These potential appetite-suppressant effects of (S)-CE-
123 would suggest that the increases in lever pressing seen in the 
FR5 and PROG/chow feeding choice studies are not due to an 
increase in appetite. Drugs that inhibit DAT bind across a broad 
range of affinities, which is potentially related to differences in 
potency seen in behavioral experiments. High-affinity drugs such 
as d-amphetamine, methylphenidate, PRX-14040, and GBR12909 
have a relatively high potency for reversing the effects of TBZ 
(Salamone et al., 2016a; Yohn et al., 2016a; Yohn et al., 2016b; Yohn 
et al., 2016c). In contrast, compounds with lower DAT binding 
affinities such as bupropion, modafinil, and (S)-CE-123 tend to be 
less potent at reversing the effects of TBZ (i.e., they require higher 
doses; Nunes et al., 2013; Salamone et al., 2017; present studies).
Future studies should examine a larger group of atypical DAT 
blockers to determine the overall relation between the neurochemical 
characteristics of these compounds (e.g. DAT affinity, selectivity 
and binding locus, effects on DAT trafficking (Mash et al., 2002; 
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